Memphis Pharmaceuticals results, Fiscal year 2026
Net profit, assets, equity and cash flow for Fiscal year 2026, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit480 millionEGP · −5.0% vs the same period a year earlier
Total assets1.49 billionEGP · −0.2% vs the same period a year earlier
Shareholders' equity843 millionEGP · +9.4% vs the same period a year earlier
Operating cash flow220 millionEGP · +153.5% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Fiscal year 2026 was about 480 million EGP, down −5.0% from 505 million EGP in Fiscal year 2025.
- Total assets at the end of Fiscal year 2026 were about 1.49 billion EGP, and shareholders' equity about 843 million EGP.
- Operating cash flow for Fiscal year 2026 was positive at 220 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2025Change
Net profit480 million505 million−5.0%
Gross profit707 million684 million+3.3%
Total assets1.49 billion1.49 billion−0.2%
Total liabilities647 million722 million−10.5%
Shareholders' equity843 million771 million+9.4%
Total liabilities and equity1.49 billion1.49 billion−0.2%
Operating cash flow220 million86.89 million+153.5%
Investing cash flow63.35 million111 million−43.0%
Financing cash flow-351 million-39.21 million−794.9%
Net change in cash-67.24 million159 million−142.4%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy